Omega Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-97.43	-102.7	-68.28	-29.45	-17.95
Depreciation & Amortization	6.77	5.19	1.39	1.15	0.79
Share-Based Compensation	8.79	7.75	3.18	0.64	0.34
Other Operating Activities	-9.65	-8.76	6.1	1.53	1.14
Operating Cash Flow	-91.51	-98.52	-57.61	-26.13	-15.68
Capital Expenditures	-2.22	-1.38	-1.47	-1.81	-0.89
Change in Investments	49.73	-16.68	-38.93	0	0
Investing Cash Flow	47.52	-18.06	-40.4	-1.81	-0.89
Share Issuance / Repurchase	40.22	0.71	128.39	0.1	0.02
Debt Issued / Paid	1.62	0	8	0	4
Other Financing Activities	-0.02	-	125.15	48.52	7.96
Financing Cash Flow	41.82	0.71	261.54	48.62	11.99
Net Cash Flow	-2.17	-115.87	163.53	20.68	-4.58
Free Cash Flow	-93.73	-99.9	-59.08	-27.94	-16.56
Free Cash Flow Margin	-3029.38%	-4818.86%	-41025.00%	-	-
Free Cash Flow Per Share	-1.74	-2.09	-2.64	-7.15	-1.32

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).